Development
Takeda Pharmaceutical Company Limited
TAK
$15.52
$0.211.37%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 29.69B | 29.94B | 29.98B | 29.77B | 30.06B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.69B | 29.94B | 29.98B | 29.77B | 30.06B |
| Cost of Revenue | 9.56B | 9.37B | 9.20B | 9.12B | 9.58B |
| Gross Profit | 20.13B | 20.57B | 20.77B | 20.65B | 20.48B |
| SG&A Expenses | 7.30B | 7.34B | 7.39B | 7.37B | 7.37B |
| Depreciation & Amortization | 4.05B | 4.08B | 3.45B | 3.47B | 3.71B |
| Other Operating Expenses | 829.49M | 886.80M | 732.01M | 698.46M | 947.39M |
| Total Operating Expenses | 26.68B | 26.60B | 25.54B | 25.34B | 26.31B |
| Operating Income | 3.01B | 3.34B | 4.44B | 4.43B | 3.75B |
| Income Before Tax | 1.10B | 1.44B | 2.57B | 2.79B | 1.96B |
| Income Tax Expenses | -174.50M | 41.87M | 394.60M | 451.59M | -42.55M |
| Earnings from Continuing Operations | 1.27K | 1.40K | 2.18K | 2.34K | 2.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -747.50K | -659.60K | -178.80K | -152.70K | 8.70K |
| Net Income | 1.27B | 1.40B | 2.18B | 2.34B | 2.00B |
| EBIT | 3.01B | 3.34B | 4.44B | 4.43B | 3.75B |
| EBITDA | 7.46B | 7.78B | 8.82B | 8.78B | 8.14B |
| EPS Basic | 0.81 | 0.90 | 1.40 | 1.51 | 1.29 |
| Normalized Basic EPS | 0.71 | 0.85 | 1.30 | 1.42 | 1.10 |
| EPS Diluted | 0.81 | 0.89 | 1.39 | 1.50 | 1.28 |
| Normalized Diluted EPS | 0.71 | 0.85 | 1.30 | 1.41 | 1.09 |
| Average Basic Shares Outstanding | 6.24B | 6.23B | 6.22B | 6.21B | 6.21B |
| Average Diluted Shares Outstanding | 6.27B | 6.26B | 6.25B | 6.24B | 6.24B |
| Dividend Per Share | 1.33 | 1.33 | 1.33 | 1.33 | 1.43 |
| Payout Ratio | 159.85% | 143.59% | 93.03% | 88.50% | 103.84% |